"The primary goal of this project is to establish a complete hospital-based liver cancer database, profiles for data feature extraction,develop different cancer, prediction models. A Medical AI program to predict the poster treatment (including operationradiofrequency ablation) recurrence of liver cancer will be established. The program system will assist doctors in the medical decision, identify high-risk patients,adjust clinical follow-up programs."

A high-sensitivity quantitative ELISA detection system for the large HBV surface (LHBS) protein was developed. It includes monoclonal antibodies for LHBSchemiluminescent sandwich ELISA method. Clinical tests of the ELISA prodcuts have been performed in CHB cases. The LHBS detection methodsproducts have been filed for US provisional patentwill be submitted for the IVD approval.

Our previous studies suggested that increase Cisd2 levels may attenuate the pathogenesis of NAFLD/NASH. Accordingly, potent Cisd2 activators with the capacity to enhance Cisd2 levels were identified through the screening of skeletally diverse collections and structural optimization. So far BPRCD0001S0 is the most potent Cisd2 activator obtained, which has been studied extensively. Data obtained revealed that BPRCD0001S0 has no detectable toxicity in vivo, can activate Cisd2 in liver and ameliorate obese-related and fructose-induced NAFLD/NASH.